<DOC>
	<DOCNO>NCT01711801</DOCNO>
	<brief_summary>This randomize , Investigator/Subject-blind , adaptive single-ascending-dose , placebo-controlled , parallel study evaluate safety , tolerability , pharmacokinetics ( include effect food ) , pharmacodynamics RO5545965 follow oral administration healthy male volunteer . In Part 1 , subject randomize cohort receive single ascending dos RO5545965 placebo . In Part 2 , subject receive 2 dos RO5545965 , feed fasted state , randomize sequence washout period approximately 2 week treatment period .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics ( Including Food Effect ) And Pharmacodynamics RO5545965 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer , 18 45 year age , inclusive . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , serology urinalysis Body mass index ( BMI ) 18 30 kg/m2 inclusive Male subject ( whether surgically sterilize ) female partner childbearing potential must use two form contraception , one must barrier method , duration study 77 day last dose History presence clinically significant disease disorder Any condition disease would render subject unsuitable study , place subject undue risk interfere ability subject complete study opinion investigator History clinically significant hypersensitivity allergic drug reaction Any suspicion history alcohol abuse and/or consumption drug abuse Regular smoker ( &gt; 5 cigarette , &gt; 1 pipeful &gt; 1 cigar per day ) Positive hepatitis B , hepatitis C HIV infection Dietary restriction would prohibit consumption standardize meal Participation investigational drug device study within 90 day prior screen , calculate followup previous study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>